Control
Dec 31 2022 |
et al., The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(22)00261-2 | Dipeptidyl peptidase-1 inhibition in patients hospitalised with COVID-19: a multicentre, double-blind, randomised, parallel-group, placebo-controlled trial |
| 41% higher mortality (p=0.02) and 39% worse 7-point scale results (p=0.007). RCT 406 hospitalized COVID-19 patients in the UK showing higher mortality and worse clinical status with brensocatib (DPP-1 inhibitor) vs. placebo. Although blood neutrophil elastase activity was reduced, indicating the desired pharmacolo.. | ||